Cell Therapy Day – Monday, March 27th

All sessions will take place in Room: Les Goudes 2

​

09:00-10:30

CT1. Cell procurement and processing

Chairs:                  Riccardo Saccardí, Italy & Sergio Querol, Spain

09:00-09:30         Practical aspects of G-CSF administration for peripheral blood stem cell collection: Mutlu Arat, Turkey

09:30-10:00         Management of donor side-effects: Jörg Halter, Switzerland

10:00-10:30         Full automation of the cryopreservation and thawing of minimally manipulated cell products:
                              Boris Calmels, France

 

11:00-12:30

CT2. Joint ISCT-EBMT Session on substantially manipulated cell products - Manufacturing immune cellular therapies to target malignancies

Chairs:                  Mark Lowdell, UK & Christian Chabannon, France

11:00-11:30         Mechanisms of resistance to immune therapies: John Barrett, USA

11:30-12:00         Improving tumor specific T cells: Catherine Bollard, USA

12:00-12:30         CAR expressing NK cells: good candidate for “off the shelf ATMP”: Ulrike Köhl, Germany

 

14:30-16:00

CT3. Joint ISCT-EBMT Session on substantially manipulated cell products - Part II: Clinical challenges in bringing immune therapies to the clinic

Chairs:                  Chiara Bonini, Italy & Catherine Bollard, USA

14:30-14:50         Cell procurement as the first step to manufacture advanced cell therapies: Adrian Gee, USA

14:50-15:10         Management of complications: He Huang, China

15:10-15:30         Point of care manufacturing of immune cells: Waseem Qasim, UK

15:30-16:00         The Joint ISCT-EBMT award for best abstract in cellular therapy

                              Presented by: Catherine Bollard, USA & Mohamad Mohty, France

                              Two-pronged Cell Therapy: Engineering NK cells to target CD22 and redirect bystander T cells to CD19 for the
                              adoptive immunotherapy of B-cell malignancies: Arpad Szoor, USA 

​

16:30-18:00

CT4. EBMT & European institutions: Working towards the accelerated development of cellular therapies to tackle cancer and other debilitating disorders of the hematopoietic system

Chairs:                  Jürgen Kuball, Germany & Marcelo Pasquini, USA

16:30-16:50         European Union support to cell therapy & Horizon 2020: David Gancberg, Belgium

16:50-17:10         Regulations: Public Health: Stefaan van der Spiegel, Belgium

17:10-17:30         The EuroGTP II Project – good practices applied to tissues and cells (T&C) preparation processes and patient follow-
                              up procedures: Esteve Trias Adroher, Spain

17:30-18:00         Round table: Professional societies facing challenges and opportunities

                              Chiara Bonini, Italy

                              Marcelo Pasquini, USA

                              Jürgen Kuball, Germany